VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GALT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GALTGalectin Therapeutics Inc.
$2.98$196M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
GALT logo

Galectin Therapeutics Inc.

GALT
NASDAQ · Metabolic & Cardiovascular Biotech
$2.98
At close - Nov 18, 4:00 PM EST - USD
Market Cap$196M
P/E-11.5x
52W High$7.13
Volume233.68K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Zero Revenue and Debt Overhang Cloud Galectin Outlook

Galectin Therapeutics appears to be a pre-revenue, binary-outcome biotech whose equity value rests almost entirely on pipeline optionality, as the company reported no revenue across all ten quarters through 2026Q2 while cutting quarterly R&D 81% from $11.1M in 2024Q4 to $2.1M in 2026Q2, narrowing the quarterly…

GrowthStable
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

GALT price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-139% Peers

P/E is 139% below peer median

03

Market leadership

RS 48 · Lag

Laggard (Underperforming 52% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 16

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
GALT-26.42%
S&P 500 (^GSPC)+6.88%
1-Year Return
GALT-51.86%
S&P 500 (^GSPC)+10.62%
3-Year Return
GALT+59.36%
S&P 500 (^GSPC)+72.22%
5-Year Return
GALT+10.37%
S&P 500 (^GSPC)+65.93%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$31M+34.5% YoY
Free cash flow FY25
-$24M+42.8% YoY
Operating margin FY25
-
ROIC (FY25)-
Avg ROIC 5Y-
ROE (FY25)-
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 16, 2026
-$0.04+20.0%
vs -$0.05
—
vs —
Q3 2026
Aug 14, 2026
-$0.14-55.6%
vs -$0.09
—
vs —
Q2 2026
May 15, 2026
-$0.08-33.3%
vs -$0.06
—
vs —
Q2 2026
Mar 31, 2026
-$0.08+20.0%
vs -$0.10
—
vs $36M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·12h ago
All You Need to Know About Galectin Therapeutics (GALT) Rating Upgrade to Buy

Galectin Therapeutics (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire·2d ago
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update

NORCROSS, Ga., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2026.

GlobeNewsWire·Nov 5, 2026
Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026

Galectin Therapeutics will present new clinical findings at American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver. These results will be covered in one oral presentation and two posters including a Poster of Distinction.

GlobeNewsWire·Oct 6, 2026
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.

Filtered for Galectin Therapeutics Inc.More Headlines
04

Compare before deciding

Benchmark GALT against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Galectin Therapeutics Inc. (GALT)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
GALT logoGALTGalectin Therapeutics Inc.Current
$2.98$196.25M-11.51————
HALO logoHALOHalozyme Therapeutics, Inc.
$95.80$11.36B24.2037.55%26.93%544.26%—
AKBA logoAKBAAkebia Therapeutics, Inc.
$0.41$109.69M-2.5447.46%-22.6%-169.15%—
MDGL logoMDGLMadrigal Pharmaceuticals, Inc.
$398.08$9.18B-77.62432.05%-10.89%-27.07%—
ELVN logoELVNEnliven Therapeutics, Inc.
$44.89$3.21B-30.85——-16.91%—
HIMS logoHIMSHims & Hers Health, Inc.
$17.05$3.8B-20.8959%-6.65%-45.81%—

Compare GALT vs Peers

Galectin Therapeutics Inc. (GALT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HALO

Most directly comparable listed peer for GALT.

Scale Benchmark

vs ALNY

Larger-name benchmark to compare GALT against a more recognizable public peer.

Peer Set

Compare Top 5

vs HALO, AKBA, MDGL, ELVN

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

GALT SEC Filings & Documents

Galectin Therapeutics Inc. (GALT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 14, 2026·SEC

Material company update

Aug 4, 2026·SEC

Material company update

Jun 23, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 31, 2026·SEC

FY 2025

Mar 31, 2025·SEC

FY 2024

Mar 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 14, 2026·SEC

FY 2026

May 15, 2026·SEC

FY 2025

Nov 14, 2025·SEC

Get notified when GALT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

GALT Frequently Asked Questions

Galectin Therapeutics Inc. (GALT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is GALT profitable?

No. Galectin Therapeutics Inc. (GALT) reported a net loss of $23.2M over the trailing twelve months.

Dividend & Returns
What is Galectin Therapeutics Inc.'s free cash flow?

Galectin Therapeutics Inc. (GALT) had negative free cash flow of $14.6M over the trailing twelve months.

What if you invested $1,000 in GALT back in 2000?

Total return calculator · dividends reinvested · 26+ years of data

See returns →